Key result
Coexisting protein S deficiency and APC resistance linked to recurrent venous thrombosis and ischemic stroke.
Why the study?
The coexistence of hereditary protein S deficiency and activated protein C resistance causing recurrent venous thrombosis and ischemic stroke in the same patient has been rarely reported.
Case Report (n=1)
No
Direct oral anticoagulants like dabigatran may represent an appealing alternative to vitamin K antagonists in poorly compliant patients with multiple hereditary clotting defects.
Answers are grounded in this paper and cite their sources.
Rare dual thrombophilia in recurrent VTE and stroke supports targeted testing; leaves open prevalence and management optimization.
The dual coagulation disorder hereditary protein S deficiency and activated protein C (APC) resistance, which clinically manifests with recurrent venous thrombosis and multifocal ischemic stroke, has only rarely been reported in the same patient. The patient is a 54-year-old male with a history of recurrent, asymptomatic ischemic stroke or transient ischemic attack (TIA) since age 14 and four episodes of deep vein thromboses (DVT), two complicated by pulmonary embolism, attributed to hereditary protein S deficiency and homozygous factor V Leiden mutation. In addition, the medical history was positive for obesity, previous chronic alcoholism, smoking, gynecomastia with left breast resection, arterial hypertension, hepatic steatosis, and cholecystolithiasis. Because of low compliance, long-term oral anticoagulation with phenprocoumon from the age of 38 was replaced by dabigatran (300 mg/d) after another stroke with bleeding at the age of 54. In summary, the simultaneous presence of two hereditary coagulation disorders can lead to multiple venous thromboses and recurrent ischemic stroke. An appealing therapeutic option in poorly compliant patients with these two hereditary clotting defects is the replacement of long-term anticoagulation with a vitamin K antagonist (VKA) by a direct oral anticoagulant.
No takes yet. Share an insight, caveat, or question.
Josef Finsterer (2023) conducted a case report in Hereditary protein S deficiency and activated protein C resistance (n=1). Dabigatran vs. Phenprocoumon was evaluated. The simultaneous presence of hereditary protein S deficiency and activated protein C resistance can lead to multiple venous thromboses and recurrent ischemic strokes.
Synapse has enriched 10 related papers. Consider them for comparative context: